C-RAD

Transaction in Own Shares • Jul 19, 2023

C-RAD AB has decided to repurchase own shares in connection to C-RAD's long term performance plan

Following the mandate from the Annual General Meeting held on May 5, 2023, the Board of Directors of C-RAD AB (publ) has decided to repurchase own shares

The reason for the mandate to repurchase own shares, and the Board of Directors' decision to utilize this mandate, is to ensure the delivery of shares in connection with C-RAD's outstanding long-term performance share plan, 2023/2026. The repurchase of own shares will be conducted in accordance with the Nordic Main Market Rulebook for Issuers of Shares.

The repurchases will be conducted in accordance with the following conditions:

• Acquisitions may be conducted on one or more occasions until the next Annual General Meeting.
• A maximum of 88,500 class B shares may be acquired.
• Acquisitions of shares are to be conducted on Nasdaq Stockholm at a price per share within the registered share price range on each occasion, by which is meant the difference between the highest buying price and the lowest selling price.
• Payment for the shares shall be made in cash.

Reporting will be made to Nasdaq Stockholm in accordance with applicable rules.

At the date of issue of this press release, the total number of C-RAD shares was 862 887 class A shares and 32 904 048 class B shares. C-RAD does not hold any own shares at the time of this press release.

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com Christoffer Herou, CFO, +46 (0)725 82 86 16, investors@c-rad.com Press Release 19 July 2023 15:25:00 CEST

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit http://www.c-rad.com

This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-19 15:25 CEST.

Attachments

C-RAD AB has decided to repurchase own shares in connection to C-RAD's long term performance plan